Dr. Pravin U. Dugel: Oxurion NV Reports Positive Topline Phase 1 Results with THR-149
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or drug-related serious adverse events reported. Rapid onset of action starting at Day 1 with increasing average improvement in Best Corrected Visual […]